Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution

Citation
Y. Ionov et al., Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution, P NAS US, 97(20), 2000, pp. 10872-10877
Citations number
47
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
ISSN journal
00278424 → ACNP
Volume
97
Issue
20
Year of publication
2000
Pages
10872 - 10877
Database
ISI
SICI code
0027-8424(20000926)97:20<10872:MIOTPG>2.0.ZU;2-X
Abstract
A remarkable instability at simple repeated sequences characterizes gastroi ntestinal cancer of the microsatellite mutator phenotype (MMP). Mutations i n the DNA mismatch repair gene family underlie the MMP, a landmark for here ditary nonpolyposis colorectal cancer. These tumors define a distinctive pa thway for carcinogenesis because they display a particular spectrum of muta ted cancer genes containing target repeats for mismatch repair deficiency. One such gene is BAX, a proapoptotic member of the Bcl-2 family of proteins , which plays a key role in programmed cell death. More than half of colon and gastric cancers of the MMP contain BAX frameshifts in a (G)(8) mononucl eotide tract. However, the functional significance of these mutations in tu mor progression has not been established. Here we show that inactivation of the wild-type BAX allele by de novo frameshift mutations confers a strong advantage during tumor clonal evolution. Tumor subclones with only mutant a lleles frequently appeared after inoculation into nude mice of single-cell clones of colon tumor cell lines with normal alleles. In contrast, no clone s of BAX-expressing cells were found after inoculation of homozygous cell c lones without wild-type BAX. These results support the interpretation that BAX inactivation contributes to tumor progression by providing a survival a dvantage. In this context, survival analyses show that BAX mutations are in dicators of poor prognosis for both colon and gastric cancer of the MMP.